Guinea-Bissau vaccine trial: WHO and researchers’ positions

WHO's February 13, 2026 statement raised scientific and ethical objections to a proposed hepatitis B birth-dose vaccine trial in Guinea-Bissau. The researchers replied on February 14. Reading both documents makes the disagreement more specific than a clash between supporters and opponents of vaccination.

Both statements recognize the birth dose's established protection against mother-to-child transmission. Their disagreement concerns what broader question the proposed trial could ethically investigate, what comparator is acceptable and how participants would be protected in a setting where national implementation was still pending.

WHO’s objections were tied to the publicly described design

WHO said withholding a proven intervention from some participants would expose newborns to serious potential harm. It questioned the scientific necessity of a no-treatment arm and the strength of the proposed safety rationale, and raised concerns about bias and safeguards, including maternal screening and protection of exposed newborns.

The statement repeatedly qualified its assessment as based on publicly available descriptions. That limitation belongs in the account: it is an institutional assessment of the described protocol, not evidence that this article has independently inspected every trial document.

WHO also said Guinea-Bissau had suspended the study pending further technical review. That is the status recorded in the February statement, rather than a claim that this revision has established the trial's operational status in November.

The researchers disputed the baseline comparison

In their reply, the researchers argued that enrolled children would receive no fewer vaccines than under existing national practice. They described all children receiving hepatitis B vaccination at six, ten and fourteen weeks, with half also receiving the birth dose.

They said the trial concerned broader health effects when the birth dose was co-administered with BCG and oral polio vaccine, not a test of whether the birth dose prevents hepatitis B transmission. They also reported national ethics approval and parental-consent plans; those are assertions in their response, not an independent verification by UnliveNews of the approval file or consent process.

The reply acknowledged the implementation pause and described openness to further discussion. It said maternal screening was not in the original protocol, citing ethical and logistical concerns about identifying infected mothers without assured access to treatment and continuing care.

Existing practice and the desired standard are different reference points

The central disagreement can be expressed without treating the positions as equivalent conclusions. The researchers compared the proposed allocation with existing national practice. WHO argued that scarcity does not justify withholding a proven protective intervention within research.

A comparison with current practice asks whether the trial reduces what people would otherwise receive. A comparison with the relevant protective standard asks what researchers owe participants once they are conducting the study. Showing an improvement against the first baseline does not, by itself, settle the second question.

This explains why the response does not simply refute WHO by pointing to later scheduled doses. The disagreement concerns the added birth dose and the protections during the relevant period, rather than whether every participant eventually receives any hepatitis B vaccine at all.

State the comparator instead of guessing the protocol

The earlier article speculated about a stepped-wedge rollout and possible rescue arrangements without identifying such provisions in the cited study. Those suggestions have been removed. A plausible alternative design is not the same thing as the design under discussion.

The researchers' response says an injectable saline placebo was not permitted by the national ethics committee and that they were open to considering vitamin K as a comparator. Describing a possible modification does not establish that it was adopted, approved or used.

Similarly, general commentary about research ethics cannot replace the exact allocation and safeguards. To assess a revised protocol, a reader would need to know which version is being evaluated and which changes are actually documented. Neither support for research nor criticism of the original proposal supplies those missing details.

A pause is not a trial result

The two February statements document a dispute and a pause. They do not report randomized outcome data demonstrating benefit or harm from the proposed allocation. It would be wrong to describe the controversy as if the study had already produced such results.

WHO's statement records a national decision in 2024 to add the birth dose, with introduction planned by 2028; the researchers' reply also refers to 2028. A planned implementation date is likewise not proof that implementation has been completed.

Keeping these categories separate preserves the public-health issue without inventing a resolution. The established protective role of the birth dose, the proposed broader research question, ethical acceptability of a comparator and actual implementation status each require their own evidence. The February exchange is valuable precisely because it shows where the parties agreed and where their reasoning diverged.